Patients' attitude to subcutaneous immunoglobulin substitution as home therapy

被引:54
作者
Kittner, J. M.
Grimbacher, B.
Wulff, W.
Jaeger, B.
Schmidt, R. E.
机构
[1] Hannover Med Sch, D-30625 Hannover, Germany
[2] Univ Hosp Freiburg, D-79106 Freiburg, Germany
关键词
immunoglobulin replacement therapy; subcutaneous application; intravenous infusion; treatment satisfaction; quality of life;
D O I
10.1007/s10875-006-9031-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction. Since 2003, immunoglobulin preparations have been approved for subcutaneous (s.c.) use in Germany. Although all our adult patients on intravenous (i.v.) substitution were offered to switch to s.c. home therapy, approximately half of them refused to change. Methods. To evaluate patients' attitude towards s.c. home therapy, a questionnaire was developed and sent to 125 patients. Questions had to be answered by ticking numbers on a Likert scale from 1 (not at all) to 8 (very much). Four scales of the Freiburg Personality Inventory (FPI) were added. From the 70 questionnaires returned (56%), 61 could be analysed (i.v. n = 28, s.c. n = 33). Results. The i.v. treated patients were afraid of being more busy with self-administration (6.9 +/- 2.1). This was not a serious concern in the s.c. treated group (3.6 +/- 1.8, p < 0.001). Many i.v. treated patients worried about severe adverse reactions at home (4.7 +/- 2.8), but patients in the s.c. group did not (1.7 +/- 1.0, p < 0.001). The statement "I dislike to puncture myself" reached 5.3 +/- 2.7 points in the i.v. treated group, but only 2.0 +/- 1.1 (p < 0.001) in the s.c. treated patients. As main reason, patients on i.v. substitution considered s.c. therapy as inconvenient (48%). Secondly, they were afraid of side effects (31%). All patients on s.c. therapy appreciated the new treatment (7.2 +/- 1.0). Main advantage for them was an increase of flexibility (6.6 +/- 1.6). The FPI displayed lower values for s.c. treated patients in the scales "Physical Complaints" and "Emotional Lability". Conclusion. Those patients who had changed to s.c. therapy were highly satisfied. However, others preferred to stay on i.v. treatment for different reasons. Perception of inconvenience, anxiety of side effects, but also personal traits may play a role.
引用
收藏
页码:400 / 405
页数:6
相关论文
共 13 条
  • [1] The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
    Chapel, HM
    Spickett, GP
    Ericson, D
    Engl, W
    Eibl, MM
    Bjorkander, J
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (02) : 94 - 100
  • [2] FAHRENBERG HS, 2001, FREIBURG PERSONALITY
  • [3] GARDULF A, 1993, CLIN EXP IMMUNOL, V92, P200
  • [4] Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home
    Gardulf, A
    Nicolay, U
    Asensio, O
    Bernatowska, E
    Böck, A
    Costa-Carvalho, BT
    Granert, C
    Haag, S
    Hernández, D
    Kiessling, P
    Kus, J
    Matamoros, N
    Niehues, T
    Schmidt, S
    Schulze, I
    Borte, M
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (04) : 936 - 942
  • [5] GARDULF A, 1995, LANCET, V345, P365
  • [6] GARDULF A, 1991, LANCET, V338, P162
  • [7] Gardulf A, 1993, Immunodeficiency, V4, P81
  • [8] LIFELONG TREATMENT WITH GAMMA-GLOBULIN FOR PRIMARY ANTIBODY DEFICIENCIES - THE PATIENTS EXPERIENCES OF SUBCUTANEOUS SELF-INFUSIONS AND HOME THERAPY
    GARDULF, A
    BJORVELL, H
    ANDERSEN, V
    BJORKANDER, J
    ERICSON, D
    FROLAND, SS
    GUSTAFSON, R
    HAMMARSTROM, L
    NYSTROM, T
    SOEBERG, B
    SMITH, CIE
    [J]. JOURNAL OF ADVANCED NURSING, 1995, 21 (05) : 917 - 927
  • [9] Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
    Högy B.
    Keinecke H.-O.
    Borte M.
    [J]. The European Journal of Health Economics, 2005, 6 (1) : 24 - 29
  • [10] Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home
    Nicolay, U
    Kiessling, P
    Berger, M
    Gupta, S
    Yel, L
    Roifman, CM
    Gardulf, A
    Eichmann, F
    Haag, S
    Massion, C
    Ochs, HD
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (01) : 65 - 72